Why Do Weight-Loss Injections Not Work for Some People?
In this article
Although GLP-1 receptor agonists (semaglutide, tirzepatide, etc.) have achieved revolutionary success in treating obesity, clinical trials and real-world evidence (RWE) show one common point: The drug does not produce the same biological response in every patient. In some individuals, weight loss never begins, while others quickly reach a "metabolic plateau" (a halt in weight loss). This results from genetic variations, hormone resistance, epigenetic memory, and differences in the gastrointestinal autonomic system rather than a lack of patient motivation. This analysis presents the scientific anatomy of resistance to weight-loss injections.
Individual Variation in Weight-Loss Success
In the clinical literature, patients using weight-loss injections are generally divided into "high responders" and "inadequate responders." Research shows that this difference concerns biological background rather than dosage.
1. Genetic Variations: GLP1R Gene Polymorphism
For the drug administered by injection, tissue GLP-1 receptors (GLP1R) are the binding sites through which it works. However, genetic research has confirmed that the structure of this receptor differs between individuals. Single-Nucleotide Polymorphisms (SNP) , as these variations are called, can reduce the receptor's sensitivity to the drug. If the receptor does not provide a "perfect fit" for the drug, the satiety signal cannot be transmitted to the brain with sufficient strength, even at the highest dose.
2. Epigenetic Memory and Adipocyte Defense
Nature (2024-2025) data show that fat cells (adipocytes) retain their past obese state as a "memory" at the DNA level. When the body begins to lose weight, this epigenetic memory activates, increasing appetite hormones (ghrelin) to return the body to its "old weight" while developing resistance to the satiety injection. This is one of the most important cellular reasons why the drug's effect diminishes over time or never begins.
3. Gastrointestinal and Autonomic Nervous System Differences
The main mechanism of GLP-1 drugs is to slow gastric emptying. However, the vagus nerve (the main connection between the brain and stomach), when it has low sensitivity in an individual, prevents the drug from sufficiently affecting gastric motility. Particularly in people with a long history of diabetes or chronic digestive problems, "gastric signaling" may be impaired, limiting the drug's ability to produce satiety.
4. "Metabolic Adaptation" (Starvation Response)
When the drug suppresses appetite and calorie intake suddenly drops, some metabolisms perceive this as a "threat." The body enters survival mode by reducing its basal metabolic rate (BMR) much more than expected. Although the drug appears to be working, the body's %20-30 reduction in energy expenditure can halt weight loss entirely (plateau phase).
5. Hedonic Hunger and Dominance of the Reward Mechanism
GLP-1 hormones regulate "physical hunger." However, in some brains, eating has become a highly dopaminergic (reward-focused) process. If a person's urge to eat is based on emotional stress or dopamine seeking (hedonic hunger) rather than biological hunger, the "satiety" created by a GLP-1 injection may not be enough to suppress this psychological urge.
🧬 GENETIC PREDISPOSITION
In one out of every 10 patients who do not respond, the primary cause is genetic receptor insensitivity. This is not about willpower, but an entirely biochemical mismatch.
🥩 MUSCLE MASS AND METABOLISM
People who do not perform resistance exercise or consume enough protein while using the drug experience muscle loss. Muscle loss is the biggest mistake that undermines the drug's weight-loss effect by slowing metabolism.
🌡️ STORAGE CONDITIONS (PSEUDO-RESISTANCE)
Scientific articles emphasize that the effectiveness of protein-based drugs whose cold chain has been disrupted (through freezing or excessive heating) can fall by up to %90. In patients who see no effect, the first things to check are "refrigerator temperature" and storage conditions.
Scientific Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Study). The New England Journal of Medicine, 2021.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
- Hanyaloglu AC. Genetic and structural variations in the GLP-1 receptor. Nature Reviews Endocrinology, 2024.
- ETH Zurich Studies. Adipose tissue carries an epigenetic memory of obesity. Nature Journal, December 2024 / January 2025.
- Müller TD, et al. GLP-1 receptor agonists in obesity: Mechanistic insights and future directions. Molecular Metabolism, 2025 Review.
- Frias JP, et al. Tirzepatide vs Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM, 2021/2022.
Editor's Note: Resistance to weight-loss injections is a multifactorial process. If you have not lost at least %5 of your starting weight despite 12-16 weeks of treatment, you are advised to discuss this with your specialist physician and assess options for molecular rotation (switching drugs) or metabolic support.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.